Provided by Tiger Trade Technology Pte. Ltd.

Cabaletta Bio

3.13
-0.0600-1.88%
Post-market: 3.180.0500+1.60%19:30 EDT
Volume:4.40M
Turnover:14.19M
Market Cap:532.10M
PE:-2.03
High:3.34
Open:3.20
Low:3.09
Close:3.19
52wk High:4.23
52wk Low:1.40
Shares:170.00M
Float Shares:141.48M
Volume Ratio:0.66
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5420
EPS(LYR):-2.1000
ROE:-93.20%
ROA:-48.19%
PB:2.53
PE(LYR):-1.49

Loading ...

Cabaletta Bio financing overhang concerns should be addressed, says Cantor

TIPRANKS
·
May 04

Cabaletta Bio Price Target Maintained With a $30.00/Share by Cantor Fitzgerald

Dow Jones
·
May 04

Cabaletta Bio publishes corporate presentation on rese-cel CD19 CAR-T autoimmune disease program

Reuters
·
May 04

Cabaletta Bio Prices $150 Million Stock Offering

MT Newswires Live
·
May 04

Cabaletta Bio Inc - Purchase Price for Common Stock Set at $2.90 per Share

THOMSON REUTERS
·
May 04

Press Release: Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Dow Jones
·
May 04

Cabaletta Bio reports promising RESET-PV and RESET-SLE data

TIPRANKS
·
May 04

Cabaletta Bio reports rese-cel activity without preconditioning in RESET-PV pemphigus trial

Reuters
·
May 04

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Cabaletta Bio (CABA)

TIPRANKS
·
Apr 29

Cabaletta Bio signs 10-year rese-cel commercial supply deal with Cellares

Reuters
·
Apr 28

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-Cel

THOMSON REUTERS
·
Apr 28

Cabaletta Bio to present rese-cel pemphigus data without preconditioning at ASGCT 2026

Reuters
·
Apr 28

Cabaletta Bio: RESET-MG Data and Differentiated Autoimmune Strategy Underpin Buy Rating and Upside Potential

TIPRANKS
·
Apr 21

Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans

TIPRANKS
·
Apr 20

Cabaletta Bio posts corporate presentation on CD19 CAR-T candidate rese-cel in autoimmunity

Reuters
·
Apr 20

Cabaletta Bio announces annual shareholder meeting via webcast

Reuters
·
Apr 17

BRIEF-First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform

Reuters
·
Apr 15

H.C. Wainwright Remains a Buy on Cabaletta Bio (CABA)

TIPRANKS
·
Apr 06

Cabaletta Bio Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 24

Cabaletta Bio Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 24